Home > Insider Trading > Incyte Corp

Incyte Corp (INCY)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

1 - 10
Next >>

Goldman Sachs' Top Growth Investors: 34 Stocks With The Highest Investment For Growth

With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future of artificial intelligence, the Federal Reserve's interest rate cut cycle, and an economy with lower...

Keep Reading →

November 20th, 2024 - News

10 Best Immunotherapy Stocks to Buy Now

The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033.

Keep Reading →

November 18th, 2024 - Hedge Funds News

Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects

Many investors continue to be worried about Incyte’s financial prospects when the patent for the company’s blood cancer medication, Jakafi, expires in 2028.

Keep Reading →

November 16th, 2024 - News Stock Analysis

Incyte Corporation (NASDAQ:INCY) Q3 2024 Earnings Call Transcript

Operator: Greetings, and welcome to the Incyte Third Quarter Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Keep Reading →

October 31st, 2024 - News Transcripts

Incyte Corporation (NASDAQ:INCY) Q2 2024 Earnings Call Transcript

Operator: Hello, and welcome to the Incyte Second Quarter 2024 Earnings Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation.

Keep Reading →

July 31st, 2024 - News Transcripts